INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,312 | -99.8% | 236 | -99.7% | 0.00% | -100.0% |
| Q2 2023 | $5,761,901 | +19.1% | 90,997 | +1.9% | 0.04% | +26.7% |
| Q1 2023 | $4,836,461 | +243.4% | 89,316 | +235.6% | 0.03% | +275.0% |
| Q4 2022 | $1,408,519 | -38.2% | 26,616 | -45.7% | 0.01% | -38.5% |
| Q3 2022 | $2,279,000 | -23.6% | 48,976 | -6.3% | 0.01% | -27.8% |
| Q2 2022 | $2,982,000 | +106.8% | 52,246 | +121.7% | 0.02% | +50.0% |
| Q1 2022 | $1,442,000 | +119.1% | 23,562 | +46.1% | 0.01% | +71.4% |
| Q2 2021 | $658,000 | +261.5% | 16,124 | +200.7% | 0.01% | +250.0% |
| Q1 2021 | $182,000 | -9.0% | 5,362 | -14.9% | 0.00% | -33.3% |
| Q4 2020 | $200,000 | -73.9% | 6,300 | -78.9% | 0.00% | -72.7% |
| Q3 2020 | $765,000 | +238.5% | 29,820 | +238.9% | 0.01% | +175.0% |
| Q2 2020 | $226,000 | -8.9% | 8,800 | -73.5% | 0.00% | -20.0% |
| Q3 2019 | $248,000 | -2.7% | 33,234 | +69.4% | 0.01% | 0.0% |
| Q2 2019 | $255,000 | -52.2% | 19,620 | -55.3% | 0.01% | -70.6% |
| Q1 2019 | $534,000 | -17.7% | 43,872 | -23.0% | 0.02% | -45.2% |
| Q4 2018 | $649,000 | +4892.3% | 56,983 | +9397.2% | 0.03% | +3000.0% |
| Q3 2018 | $13,000 | -92.4% | 600 | -93.8% | 0.00% | -88.9% |
| Q2 2018 | $170,000 | +27.8% | 9,641 | +53.0% | 0.01% | +12.5% |
| Q1 2018 | $133,000 | -83.0% | 6,302 | -88.3% | 0.01% | -80.5% |
| Q4 2017 | $781,000 | +688.9% | 53,932 | +757.6% | 0.04% | +583.3% |
| Q3 2017 | $99,000 | -38.5% | 6,289 | -41.0% | 0.01% | -53.8% |
| Q4 2016 | $161,000 | -74.6% | 10,664 | -74.3% | 0.01% | -68.3% |
| Q3 2016 | $633,000 | +5175.0% | 41,526 | +13742.0% | 0.04% | +4000.0% |
| Q2 2016 | $12,000 | -96.6% | 300 | -97.7% | 0.00% | -95.0% |
| Q1 2016 | $357,000 | -77.5% | 12,836 | -56.6% | 0.02% | -78.5% |
| Q4 2015 | $1,590,000 | +264.7% | 29,553 | +171.7% | 0.09% | +322.7% |
| Q3 2015 | $436,000 | -26.1% | 10,879 | -41.1% | 0.02% | -24.1% |
| Q2 2015 | $590,000 | +121.0% | 18,463 | +64.8% | 0.03% | +123.1% |
| Q1 2015 | $267,000 | – | 11,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |